| Criteria | Number (%) | |
|---|---|---|
| Progressing | Slowly progressing | 20 (83,3) |
| Quickly progressing | 3 (12,5) | |
| With no marked progression | 1 (4,2) | |
| Initial manifestation | 0 | |
| Extraarticular manifestations | There are | 2 (8,3) (rheumatoid nodules in anamnesis) |
| There are no | 22 (91,7) | |
| Immunologic characteristics | RF positive | 24 (100,0) |
| RF negative | 0 | |
| antiCCP positive | 18 (75,0) | |
| antiCCP negative | 6 (25,0) | |
| Shared Epitopes | There are | 17 (70,8) |
| There are no | 7 (29,2) | |
| Activity (DAS28-ESR) | Minimal | 10 (41,7) |
| Moderate | 14 (58,3) | |
| High | 0 | |
| Roentgenologic stage | I | 0 |
| II | 0 | |
| III | 18 (75,0) | |
| IV | 6 (25,0) | |
| Joint functional deficiency (HAQ) | 0 | 4 (16,7) |
| I | 14 (58,3) | |
| II | 6 (25,0) | |
| III | 0 | |
| IV | 0 | |